Colorectal disorders:

Indications for: ENTYVIO

Moderately to severely active ulcerative colitis or Crohn’s disease.

Adult Dosage:

Give by IV infusion over 30mins. ≥18yrs: 300mg at Weeks 0, 2, and 6, then every 8 weeks thereafter. Discontinue if no therapeutic benefit by Week 14.

Children Dosage:

<18yrs: not established.

ENTYVIO Warnings/Precautions:

Complete all immunizations according to current guidelines before initiating. Monitor for hypersensitivity reactions during and after infusion. Have epinephrine and antihistamines available. Discontinue if anaphylaxis or other serious infusion-related or hypersensitivity reactions occur. Active, severe infections: not recommended until controlled. Consider withholding if severe infection develops. History of recurring severe infections. Consider tuberculosis screening. Monitor for neurological signs/symptoms (those associated with progressive multifocal leukoencephalopathy [PML]); withhold dosing if suspected; permanently discontinue if confirmed. Discontinue if jaundice or significant liver injury occurs. Pregnancy. Nursing mothers.

ENTYVIO Classification:

Integrin receptor antagonist.

ENTYVIO Interactions:

Avoid concomitant natalizumab, TNF blockers. Caution with concomitant live vaccines.

Adverse Reactions:

Nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities; infusion-related or hypersensitivity reactions, PML.


Register pregnant patients exposed to Entyvio by calling (877) 825-3327.

Generic Drug Availability:


How Supplied:

Single-use vial (20mL)—1